Company Overview
| Stock Name | Sinomab Bio-B |
|---|---|
| Stock Code | 03681 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 專門研究、發展、製造及商業化免疫性疾病療法的香港生物製藥公司,主要研製以單克隆抗體為基礎的生物藥,並開發新化學實體。 |
| Listing Date | 2019-11-12 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 香港皇后大道東183號合和中心54樓 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | sinomab.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 7.60 / shares |
| Offer Price Range | To be extracted |
| Lot Size | 300 shares |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | 2019-10-31 to 2019-11-05 |
| Global Offering Shares | 182,129,400 shares |
| HK Public Offer Shares (Initial) | 18,213,000 shares (10.0%) |
| Public Offer Lots (Initial) | 60,710lots (Pool A30,355lots,Pool B30,355lots) |
| International Placing Shares (Initial) | 163,916,400 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 1,006,240,400 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 34.0% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 1,384,183,440 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 300 | HK$ 2,280 |
| 2 lots | 600 | HK$ 4,560 |
| 3 lots | 900 | HK$ 6,840 |
| 4 lots | 1,200 | HK$ 9,120 |
| 5 lots | 1,500 | HK$ 11,400 |
| 6 lots | 1,800 | HK$ 13,680 |
| 7 lots | 2,100 | HK$ 15,960 |
| 8 lots | 2,400 | HK$ 18,240 |
| 9 lots | 2,700 | HK$ 20,520 |
| 10 lots | 3,000 | HK$ 22,800 |
| 15 lots | 4,500 | HK$ 34,200 |
| 20 lots | 6,000 | HK$ 45,600 |
| 25 lots | 7,500 | HK$ 57,000 |
| 30 lots | 9,000 | HK$ 68,400 |
| 35 lots | 10,500 | HK$ 79,800 |
| 40 lots | 12,000 | HK$ 91,200 |
| 45 lots | 13,500 | HK$ 102,600 |
| 50 lots | 15,000 | HK$ 114,000 |
| 100 lots | 30,000 | HK$ 228,000 |
| 150 lots | 45,000 | HK$ 342,000 |
| 200 lots | 60,000 | HK$ 456,000 |
| 250 lots | 75,000 | HK$ 570,000 |
| 300 lots | 90,000 | HK$ 684,000 |
| 350 lots | 105,000 | HK$ 798,000 |
| 400 lots | 120,000 | HK$ 912,000 |
| 450 lots | 135,000 | HK$ 1,026,000 |
| 500 lots | 150,000 | HK$ 1,140,000 |
| 1,000 lots | 300,000 | HK$ 2,280,000 |
| 1,500 lots | 450,000 | HK$ 3,420,000 |
| 2,000 lots | 600,000 | HK$ 4,560,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 2,500 lots | 750,000 | HK$ 5,700,000 |
| 3,000 lots | 900,000 | HK$ 6,840,000 |
| 3,500 lots | 1,050,000 | HK$ 7,980,000 |
| 4,000 lots | 1,200,000 | HK$ 9,120,000 |
| 4,500 lots | 1,350,000 | HK$ 10,260,000 |
| 5,000 lots | 1,500,000 | HK$ 11,400,000 |
| 10,000 lots | 3,000,000 | HK$ 22,800,000 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| Avg Daily HK Mkt Cap | HK$ 1.8B |
| Est. Threshold | HK$ 9.71B |
| Analysis Result | HK market cap below threshold, need +441% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 8,653,667,440 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不適用(公司處於虧損狀態) |
| Profit/Loss Status | 最近完整財年(2018年)虧損約人民幣83.6百萬元 |
| Period-End Cash Balance | 人民幣41.5百萬元 |
| Listing Expenses | ~HK$ 105,042,840 |
| Listing Expenses / Funds Raised | ~7.59% |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2017 | 2018 |
|---|---|---|
| Other income and gains, net | 3,411 | 8,666 |
| Administrative expenses | -6,992 | -8,996 |
| Net finance costs | -2,961 | -3,030 |
| Profit before tax | -51,901 | -83,610 |
| Income tax expense | 0 | 0 |
| Profit for the year | -51,901 | -83,610 |
| Profit attributable to owners | -47,974 | -83,610 |
Balance Sheet
| Item | 2017 | 2018 | 2019-04 |
|---|---|---|---|
| Cash and cash equivalents | 66,096 | 41,512 | |
| Total current assets | 126,826 | 50,270 | |
| Total assets | 161,636 | 88,819 | |
| Total current liabilities | 184,907 | 28,419 | |
| Total liabilities | 212,588 | 61,413 | |
| Total equity | -50,952 | 27,406 | |
| Equity attributable to owners | -50,952 | 27,406 | |
| Interest-bearing borrowings | 170,000 | 10,000 | 10,000 |
Cash Flow Statement
| Item | 2017 | 2018 | 2019-04 |
|---|---|---|---|
| Net cash from operating activities | -40,200 | -46,829 | |
| Net cash from investing activities | 10,315 | 21,466 | |
| Net cash from financing activities | 89,035 | -3,555 | |
| Net increase in cash | 59,150 | -28,918 | |
| Depreciation of PP&E | 12,617 | 1,075 | 493 |
| Depreciation of right-of-use assets | 1,103 | 4,267 | 1,970 |
| Purchase of PP&E | -823 | -2,746 | -10,231 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 6.0 |
|---|---|
| First Day Open | HK$ 7.3 |
| First Day Change | -21.05% |
| First Day Volume | 61345400.0 |
| First Day Turnover | 421492000.0 |
| Use of Proceeds | 1、約50.00%或643.22百萬港元將分配至研發及商業化在研藥物;
2、約40.00%或514.58百萬港元將用于建設我們的蘇州生產基地,其主要用作我們核心產品SM03的商業化規模生產;
3、約10.00%或128.64百萬港元將用于我們的營運資金、擴大內部能力及其他一般企業用途。 |
Underwriting Syndicate
Joint Sponsors (2)
Overall Coordinators (2)
Joint Bookrunners (8)
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894
ORIENT SECURITIES (HONG KONG) LIMITED CE AVD362
CHINA EVERBRIGHT SECURITIES (HK) LIMITED CE AAW536
国泰君安证券(香港)有限公司 CE ABY236
招银国际融资有限公司 CE AVM940
海通国际证券有限公司 CE AAF806
Fosun International Securities Limited CE AAF432
VICTORY SECURITIES COMPANY LIMITED CE ABN091
Joint Lead Managers (8)
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894
ORIENT SECURITIES (HONG KONG) LIMITED CE AVD362
CHINA EVERBRIGHT SECURITIES (HK) LIMITED CE AAW536
国泰君安证券(香港)有限公司 CE ABY236
招银国际融资有限公司 CE AVM940
海通国际证券有限公司 CE AAF806
Fosun International Securities Limited CE AAF432
VICTORY SECURITIES COMPANY LIMITED CE ABN091
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 瑞捷软件科技(香港)有限公司 | 78,429,720 HKD | — | 5.67% | — | 6 months | 2020-05-12 |
| 2 | 云南白药集团股份有限公司 | 392,155,440 HKD | — | 28.33% | — | 6 months | 2020-05-12 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 梁瑞安 | — |
| Company Secretary | 鄭美珍 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 緊隨紅股發行及全球發售完成後(假設超額配股權未獲行使),控股股東一致行動集團合共持有約38.71%;海南海藥持有約15.11%;Apricot Oversea持有約10.76%。 |
|---|




